Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Lymphoma, Non-Hodgkin 4Lymphoma 4Prostatic Neoplasms 3Leukemia 3Hematologic Neoplasms 3Stomach Neoplasms 2Small Cell Lung Carcinoma 2Myelodysplastic Syndromes 2Multiple Myeloma 2Lymphoma, B-Cell 2Lung Neoplasms 2Carcinoma in Situ 2Burkitt Lymphoma 2Vulvar Neoplasms 1Vulvar Diseases 1Uterine Cervical Dysplasia 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Sleep Initiation and Maintenance Disorders 1Recurrence 1Rectal Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Philadelphia Chromosome 1Peritoneal Neoplasms 1Papillomavirus Infections 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Nose Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1

Interventions

Peripheral Blood Stem Cell Transplantation 12Rituximab 9Tacrolimus 8Mycophenolic Acid 8fludarabine phosphate 7Cyclophosphamide 7Whole-Body Irradiation 6Cyclosporine 5Radiotherapy 4Methotrexate 4Granulocyte Colony-Stimulating Factor 4Filgrastim 4Busulfan 4Antilymphocyte Serum 4immunotoxin HA22 3fludarabine 3Etoposide 3Dexamethasone 3Calcium Dobesilate 3plerixafor 2merphos 2Therapeutics 2Sirolimus 2Ondansetron 2Melphalan 2Ipilimumab 2Flow Cytometry 2Diphenhydramine 2Darbepoetin alfa 2Cord Blood Stem Cell Transplantation 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia, Hairy Cell × Electrocardiography × Clear all
NCT00923013 2025-08-08

Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Active not recruiting
175 enrolled 16 charts
Other hematologic neoplasm

Leukemia, Leukemia, Hairy Cell, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡